{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:28:55Z","timestamp":1792114135581,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG-KO 3884\/5-1"],"award-info":[{"award-number":["DFG-KO 3884\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003542","name":"Ministerium f\u00fcr Wissenschaft, Forschung und Kunst Baden-W\u00fcrttemberg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009318","name":"Helmholtz Association","doi-asserted-by":"publisher","award":["SO-96"],"award-info":[{"award-number":["SO-96"]}],"id":[{"id":"10.13039\/501100009318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["101003480-CORESMA"],"award-info":[{"award-number":["101003480-CORESMA"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011736","name":"Ministerium f\u00fcr Wirtschaft, Arbeit und Wohnungsbau Baden-W\u00fcrttemberg","doi-asserted-by":"publisher","award":["FKZ-3-4332.62-NMI-67"],"award-info":[{"award-number":["FKZ-3-4332.62-NMI-67"]}],"id":[{"id":"10.13039\/501100011736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011736","name":"Ministerium f\u00fcr Wirtschaft, Arbeit und Wohnungsbau Baden-W\u00fcrttemberg","doi-asserted-by":"publisher","award":["FKZ-3-4332.62-NMI-68"],"award-info":[{"award-number":["FKZ-3-4332.62-NMI-68"]}],"id":[{"id":"10.13039\/501100011736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SARS-CoV-2 is evolving with mutations in the receptor binding domain (RBD) being of particular concern. It is important to know how much cross-protection is offered between strains following vaccination or infection. Here, we obtain serum and saliva samples from groups of vaccinated (Pfizer BNT-162b2), infected and uninfected individuals and characterize the antibody response to RBD mutant strains. Vaccinated individuals have a robust humoral response after the second dose and have high IgG antibody titers in the saliva. Antibody responses however show considerable differences in binding to RBD mutants of emerging variants of concern and substantial reduction in RBD binding and neutralization is observed against a patient-isolated South African variant. Taken together our data reinforce the importance of the second dose of Pfizer BNT-162b2 to acquire high levels of neutralizing antibodies and high antibody titers in saliva suggest that vaccinated individuals may have reduced transmission potential. Substantially reduced neutralization for the South African variant further highlights the importance of surveillance strategies to detect new variants and targeting these in future vaccines.<\/jats:p>","DOI":"10.1038\/s41467-021-23473-6","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T06:02:59Z","timestamp":1621922579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":138,"title":["Immune response to SARS-CoV-2 variants of concern in vaccinated individuals"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9243-4257","authenticated-orcid":false,"given":"Matthias","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0017-6738","authenticated-orcid":false,"given":"Alex","family":"Dulovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Ruetalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp D.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudi T.","family":"Pinilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Heinzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Haering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern","family":"Traenkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1050-5948","authenticated-orcid":false,"given":"Teresa R.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Layer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Mehrlaender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valbona","family":"Mirakaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Planatscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8066-5157","authenticated-orcid":false,"given":"Katja","family":"Schenke-Layland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3328-8808","authenticated-orcid":false,"given":"G\u00e9rard","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Strengert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6797-6812","authenticated-orcid":false,"given":"Tamam","family":"Bakchoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Althaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4716-0311","authenticated-orcid":false,"given":"Rolf","family":"Fendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5025-7221","authenticated-orcid":false,"given":"Andrea","family":"Kreidenweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koeppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5923-8986","authenticated-orcid":false,"given":"Ulrich","family":"Rothbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8989-5813","authenticated-orcid":false,"given":"Michael","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-181X","authenticated-orcid":false,"given":"Nicole","family":"Schneiderhan-Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"23473_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"23473_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"23473_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S2215-0366(20)30491-0","volume":"8","author":"K-Y Pan","year":"2021","unstructured":"Pan, K.-Y. et al. The mental health impact of the COVID-19 pandemic on people with and without depressive, anxiety, or obsessive-compulsive disorders: a longitudinal study of three Dutch case-control cohorts. Lancet Psychiatry 8, 121\u2013129 (2021).","journal-title":"Lancet Psychiatry"},{"key":"23473_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S2215-0366(20)30308-4","volume":"7","author":"M Pierce","year":"2020","unstructured":"Pierce, M. et al. Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population. Lancet Psychiatry 7, 883\u2013892 (2020).","journal-title":"Lancet Psychiatry"},{"key":"23473_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.spc.2020.10.016","volume":"26","author":"M Mofijur","year":"2021","unstructured":"Mofijur, M. et al. Impact of COVID-19 on the social, economic, environmental and energy domains: lessons learnt from a global pandemic. Sustain. Prod. Consum. 26, 343\u2013359 (2021).","journal-title":"Sustain. Prod. Consum."},{"key":"23473_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"23473_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"23473_CR8","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"23473_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan, M. J. et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589\u2013593 (2020).","journal-title":"Nature"},{"key":"23473_CR10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827.e819 (2020).","journal-title":"Cell"},{"key":"23473_CR11","doi-asserted-by":"publisher","unstructured":"Volz, E. et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature https:\/\/doi.org\/10.1038\/s41586-021-03470-x (2021).","DOI":"10.1038\/s41586-021-03470-x"},{"key":"23473_CR12","doi-asserted-by":"publisher","unstructured":"Graham, M. S. et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health https:\/\/doi.org\/10.1016\/S2468-2667(21)00055-4 (2021).","DOI":"10.1016\/S2468-2667(21)00055-4"},{"key":"23473_CR13","doi-asserted-by":"publisher","first-page":"eabg3055","DOI":"10.1126\/science.abg3055","volume":"372","author":"NG Davies","year":"2021","unstructured":"Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372, eabg3055 (2021).","journal-title":"Science"},{"key":"23473_CR14","doi-asserted-by":"publisher","unstructured":"Collier, D. A. et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature https:\/\/doi.org\/10.1038\/s41586-021-03412-7 (2021).","DOI":"10.1038\/s41586-021-03412-7"},{"key":"23473_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","volume":"592","author":"SA Kemp","year":"2021","unstructured":"Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 592, 277\u2013282 (2021).","journal-title":"Nature"},{"key":"23473_CR16","doi-asserted-by":"publisher","unstructured":"Schr\u00f6rs, B. et al. Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.02.04.429765 (2021).","DOI":"10.1101\/2021.02.04.429765"},{"key":"23473_CR17","doi-asserted-by":"publisher","unstructured":"Ou, J. et al. Emergence of SARS-CoV-2 spike RBD mutants that enhance viral infectivity through increased human ACE2 receptor binding affinity. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.03.15.991844 (2020).","DOI":"10.1101\/2020.03.15.991844"},{"key":"23473_CR18","doi-asserted-by":"publisher","unstructured":"Sun, C. et al. SARS-CoV-2 and SARS-CoV spike-RBD structure and receptor binding comparison and potential implications on neutralizing antibody and vaccine development. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.02.16.951723 (2020).","DOI":"10.1101\/2020.02.16.951723"},{"key":"23473_CR19","doi-asserted-by":"publisher","unstructured":"Cerutti, G. et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe https:\/\/doi.org\/10.1016\/j.chom.2021.03.005 (2021).","DOI":"10.1016\/j.chom.2021.03.005"},{"key":"23473_CR20","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1056\/NEJMc2025179","volume":"383","author":"FJ Ibarrondo","year":"2020","unstructured":"Ibarrondo, F. J. et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N. Engl. J. Med. 383, 1085\u20131087 (2020).","journal-title":"N. Engl. J. Med."},{"key":"23473_CR21","doi-asserted-by":"publisher","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","volume":"371","author":"JM Dan","year":"2021","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371, eabf4063 (2021).","journal-title":"Science"},{"key":"23473_CR22","doi-asserted-by":"publisher","unstructured":"Tea, F. et al. SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2020.12.19.20248567 (2020).","DOI":"10.1101\/2020.12.19.20248567"},{"key":"23473_CR23","doi-asserted-by":"publisher","unstructured":"Flehmig, B. et al. Persisting neutralizing activity to SARS-CoV-2 over months in sera of COVID-19 patients. Viruses 12, https:\/\/doi.org\/10.3390\/v12121357 (2020).","DOI":"10.3390\/v12121357"},{"key":"23473_CR24","doi-asserted-by":"publisher","unstructured":"Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature https:\/\/doi.org\/10.1038\/s41586-021-03402-9 (2021).","DOI":"10.1038\/s41586-021-03402-9"},{"key":"23473_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(21)00183-5","volume":"397","author":"EC Sabino","year":"2021","unstructured":"Sabino, E. C. et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet 397, 452\u2013455 (2021).","journal-title":"Lancet"},{"key":"23473_CR26","doi-asserted-by":"publisher","first-page":"2100009","DOI":"10.2807\/1560-7917.ES.2021.26.5.210009","volume":"26","author":"HD Larsen","year":"2021","unstructured":"Larsen, H. D. et al. Preliminary report of an outbreak of SARS-CoV-2 in mink and mink farmers associated with community spread, Denmark, June to November 2020. Eurosurveillance 26, 2100009 (2021).","journal-title":"Eurosurveillance"},{"key":"23473_CR27","doi-asserted-by":"publisher","unstructured":"Zhang, W. et al. Emergence of a novel SARS-CoV-2 variant in Southern California. J. Am. Med. Assoc. https:\/\/doi.org\/10.1001\/jama.2021.1612 (2021).","DOI":"10.1001\/jama.2021.1612"},{"key":"23473_CR28","doi-asserted-by":"publisher","unstructured":"Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature https:\/\/doi.org\/10.1038\/s41586-021-03426-1 (2021).","DOI":"10.1038\/s41586-021-03426-1"},{"key":"23473_CR29","doi-asserted-by":"publisher","unstructured":"Shen, X. et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe https:\/\/doi.org\/10.1016\/j.chom.2021.03.002 (2021).","DOI":"10.1016\/j.chom.2021.03.002"},{"key":"23473_CR30","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444 (2020).","journal-title":"Science"},{"key":"23473_CR31","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1126\/science.abc4730","volume":"369","author":"H Gu","year":"2020","unstructured":"Gu, H. et al. Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy. Science 369, 1603 (2020).","journal-title":"Science"},{"key":"23473_CR32","doi-asserted-by":"publisher","unstructured":"Planas, D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01318-5 (2021).","DOI":"10.1038\/s41591-021-01318-5"},{"key":"23473_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20973-3","volume":"12","author":"M Becker","year":"2021","unstructured":"Becker, M. et al. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. Nat. Commun. 12, 1152 (2021).","journal-title":"Nat. Commun."},{"key":"23473_CR34","doi-asserted-by":"publisher","unstructured":"Ruetalo, N. et al. Antibody response against SARS-CoV-2 and seasonal coronaviruses in nonhospitalized COVID-19 patients. mSphere 6, https:\/\/doi.org\/10.1128\/mSphere.01145-20 (2021).","DOI":"10.1128\/mSphere.01145-20"},{"key":"23473_CR35","doi-asserted-by":"publisher","unstructured":"Wagner, T. R. et al. NeutrobodyPlex\u2014nanobodies to monitor a SARS-CoV-2 neutralizing immune response. EMBO Rep. 22, e52325 https:\/\/doi.org\/10.15252\/embr.202052325 (2021).","DOI":"10.15252\/embr.202052325"},{"key":"23473_CR36","doi-asserted-by":"publisher","unstructured":"Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell https:\/\/doi.org\/10.1016\/j.cell.2021.02.037.","DOI":"10.1016\/j.cell.2021.02.037"},{"key":"23473_CR37","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum\u2014preliminary report. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2102017 (2021).","DOI":"10.1056\/NEJMc2102017"},{"key":"23473_CR38","doi-asserted-by":"publisher","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature https:\/\/doi.org\/10.1038\/s41586-021-03398-2 (2021).","DOI":"10.1038\/s41586-021-03398-2"},{"key":"23473_CR39","doi-asserted-by":"publisher","unstructured":"Kuzmina, A. et al. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe https:\/\/doi.org\/10.1016\/j.chom.2021.03.008 (2021).","DOI":"10.1016\/j.chom.2021.03.008"},{"key":"23473_CR40","doi-asserted-by":"publisher","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature https:\/\/doi.org\/10.1038\/s41586-021-03324-6 (2021).","DOI":"10.1038\/s41586-021-03324-6"},{"key":"23473_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","volume":"22","author":"A Nelde","year":"2021","unstructured":"Nelde, A. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 22, 74\u201385 (2021).","journal-title":"Nat. Immunol."},{"key":"23473_CR42","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/s41564-020-0770-5","volume":"5","author":"A Rambaut","year":"2020","unstructured":"Rambaut, A. et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 5, 1403\u20131407 (2020).","journal-title":"Nat. Microbiol."},{"key":"23473_CR43","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","volume":"26","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033\u20131036 (2020).","journal-title":"Nat. Med."},{"key":"23473_CR44","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jama.2020.27124","volume":"325","author":"AS Lauring","year":"2021","unstructured":"Lauring, A. S. & Hodcroft, E. B. Genetic variants of SARS-CoV-2\u2014what do they mean? J. Am. Med. Assoc. 325, 529\u2013531 (2021).","journal-title":"J. Am. Med. Assoc."},{"key":"23473_CR45","doi-asserted-by":"crossref","unstructured":"Planatscher, H. et al. Systematic reference sample generation for multiplexed serological assays. Sci. Rep. 3, 1\u20135 (2013).","DOI":"10.1038\/srep03259"},{"key":"23473_CR46","doi-asserted-by":"publisher","unstructured":"Sulyok, Z. et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomizedtrial. Nat. Commun. 12, 2518, https:\/\/doi.org\/10.1038\/s41467-021-22740-w (2021).","DOI":"10.1038\/s41467-021-22740-w"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23473-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23473-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23473-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T07:27:46Z","timestamp":1669966066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23473-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["23473"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-23473-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.08.21252958","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.R.W., P.K., N.S.M., and U.R. are named as inventors on a patent application (EP 20 197 031.6) claiming the use of the described Nanobodies used in the NeutrobodyPlex for diagnosis and therapeutics filed by the Natural and Medical Sciences Institute. N.S.-M. was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute at the University of Tuebingen is involved in applied research projects as a fee for services with Luminex. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3109"}}